AI Agent Governance for Clinical Supply Chain Forecasting
AI agents used to forecast clinical trial drug demand, allocate inventory across trial sites, and monitor cold-chain logistics require runtime governance that distinguishes read access from execute authority, assigns each agent a distinct identity, enforces tool-call policy before actions reach ERP or logistics systems, and logs every decision for regulatory review. Without these controls, an agent's forecasting error or unauthorized action can disrupt drug availability at a trial site, creating patient-safety and compliance exposure that operational cost frameworks do not capture.
Runtime Controls Required Before Expanding Agent Autonomy
- 1
Distinct Agent Identity
Each agent should operate under its own machine identity rather than a shared service account, so actions across ERP and logistics systems are attributable to a specific agent instance.
- 2
Task-Segmented Permissions
Permissions should be scoped by task type, forecasting, allocation, or execution, rather than granted as broad system-level access to ERP or IRT platforms.
- 3
Tool-Call Policy Enforcement
A policy enforcement point should sit between the agent's decision output and the downstream system call, evaluating whether the requested action is within approved bounds before it executes.
- 4
Separated Audit Logging
Agent inputs, reasoning outputs, and executed actions should be logged as distinct records to support post-hoc review and regulatory inquiry.
- 5
Escalation Thresholds
Supply decisions above a defined risk threshold, such as reallocating drug supply away from an active site, should require human approval before execution rather than proceeding autonomously.
Questions to Ask Before Expanding Agent Autonomy
- What specific systems and data sources is the agent permitted to access, and is that access read-only or execution-capable?
- How is agent identity established and kept distinct from human or service-account identity across ERP and logistics platforms?
- What mechanism enforces tool-call policy at runtime, and can it block or flag an out-of-policy action before it executes?
- What audit trail exists for agent decisions and actions, and can it support a regulatory inquiry into a specific supply decision?
- What is the escalation threshold above which an agent-recommended supply change requires human approval before execution?
Where AI Agents Operate in Clinical Supply Chains
Demand Forecasting
Agents analyze enrollment and consumption data to project drug demand across trial sites and phases.
Inventory Allocation
Agents recommend or execute redistribution of supply between sites based on forecasted need.
Cold-Chain Monitoring
Agents ingest logistics and temperature feeds to flag or route shipments requiring intervention.
ERP and IRT Integration
Agents read from, and in some deployments write to, inventory and randomization systems.
What These Agents Actually Do
AI agents deployed in clinical supply chain forecasting typically perform three related functions: predicting drug demand from enrollment and consumption data, recommending or executing inventory reallocation across trial sites, and monitoring cold-chain logistics feeds for deviations. To do this, they need access to a specific set of internal systems: enrollment and demand data sources, ERP or inventory management platforms, interactive response technology (IRT/IWRS) systems used in trial randomization, and cold-chain monitoring feeds. Each of these access points carries a different risk profile. Reading enrollment data to build a forecast is materially different from writing an inventory transfer instruction to an ERP system. Governance frameworks that treat all agent activity as a single category of risk miss this distinction, which is the starting point for any control design in this use case.
Why Autonomous Authority Introduces Patient-Safety Risk
General operational forecasting failures cost money. A forecasting or allocation failure in a clinical trial can leave a site without investigational drug supply, which is a direct patient-safety and protocol-integrity issue, not just an operational one. This distinction matters for governance design. An agent with autonomous authority to trigger inventory transfers or flag cold-chain deviations is making decisions that, if wrong, may require regulatory disclosure and explanation. Accountability for those decisions has to be assignable to a specific human role, and the system needs to be able to reconstruct why an agent acted the way it did. This is a different governance bar than internal supply chain automation for commercial products, where errors are corrected without patient impact.
Decisions to Make Before Granting Execution Authority
Organizations evaluating agent autonomy in this use case need to work through a sequence of decisions rather than granting full access at deployment.
- Should clinical supply chain AI agents ever have direct write access to ERP systems?
- Direct, unmediated write access is generally not advisable given the patient-safety stakes. A policy enforcement point between agent output and system execution allows the agent to recommend or initiate an action while a separate control validates it against defined rules before it reaches the ERP system.
- Is there current regulatory guidance specific to autonomous agents in clinical trial supply operations?
- No verified, agent-specific regulatory guidance exists at this time. Existing GxP change-control and recordkeeping expectations remain the relevant framework; organizations should confirm current requirements directly with FDA, EMA, and ICH rather than assuming a settled standard.
- How is accountability assigned when an agent makes an incorrect supply decision?
- Accountability should be tied to a named human role responsible for the agent's operating scope, not to the agent itself. This requires audit logs detailed enough to reconstruct the agent's inputs, reasoning output, and the action taken, so the responsible role can explain the decision if questioned.
Evaluate Runtime Governance Before Expanding Agent Autonomy
Clinical supply chain agents introduce patient-safety and regulatory exposure that generic AI governance does not address. Runtime identity, permission, and audit controls need to be in place before execution authority is granted.
Explore Runtime Governance